Differences in susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis between SD/gShi rats with spontaneous hypospermatogenesis and SD/cShi rats with spontaneous hydronephrosis

Cancer Science

Volumn 96, Issue 10, 2005, Pages 637-644

  Murai, Takashi ^a,b   Mori, Yukio ^c   Tatematsu, Kenjiro ^c   Koide, Akihiro ^c,f   Hagiwara, Akihiro ^d   Makino, Susumu ^e   Mori, Satoru ^a   Wanibuchi, Hideki ^a   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Developmental Research Laboratories   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^d Daiyukai Research Institute for Medical Science   (Japan)

^e SHIONOGI AND CO LTD   (Japan)

^f PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DEHYDROGENASE; BROMODEOXYCYTIDINE; BROXURIDINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; CYTOCHROME P450 INHIBITOR; HETEROCYCLIC AMINE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER EPITHELIUM; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; GENE ACTIVATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HYDRONEPHROSIS; IN VITRO STUDY; KIDNEY CONCENTRATING CAPACITY; MALE; MUTAGENICITY; NONHUMAN; OLIGOSPERMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RAT STRAIN; RISK ASSESSMENT; SPERMATOGENESIS; STRAIN DIFFERENCE;

ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HYDRONEPHROSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SPERMATOGENESIS; URINARY BLADDER NEOPLASMS;

EID: 28444437022     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00108.x     Document Type: Article

References (48)

1. Kuroishi T, Nishikawa Y, Tominaga S, Aoki K. Cancer mortality statistics in 33 countries (1953-1992). Gann Monogr Cancer Res 1999; 47: 153-217.
2. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S, Yamada K. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 1975; 3: 73-9.
3. Mori S, Hosono M, Machino S et al. Induction of the renal pelvic and ureteral carcinomas by N-butyl-N-(4-hydroxybutyl) nitrosamine in SD/cShi rats with spontaneous hydronephrosis. Toxicol Pathol 1994; 22: 373-9.
4. Kaneto M, Kanamori S, Kishi K. Spermatogenic defects in a new inbred strain SD/gShi male rat with small testes. J Reprod Dev 1999; 45: 375-85.
5. Quinn GP, Axelrod J, Brodie BB. Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline. Biochem Pharmacol 1958; 1: 152-9.
6. Furner RL, Gram TE, Stitzel RE. The influence of age, sex, and drug treatment on microsomal drug metabolism in four rat strains. Biochem Pharmacol 1969; 18: 1635-41.
7. Kato R. Sex-related differences in drug metabolism. Drug Metab Rev 1974; 3: 1-32.
8. Okada M, Ishidate M. Metabolic fate of N-n-butyl-N-(4-hydroxybutyl)-nitrosamine and its analogues. Selective induction of urinary bladder tumours in the rat. Xenobiotica 1977; 7: 11-24.
9. Nakanowatari J-I, Fukushima S, Imaida K, Ito N, Nagase S. Strain differences in N-butyl-N-(4-hydroxybutyl) nitrosamine bladder carcinogenesis in rats. Jpn J Cancer Res (Gann) 1988; 79: 453-9.
10. Okada M, Suzuki E, Iiyoshi M. Syntheses of N-alkyl-N-(ω-carboxypropyl) nitrosamines related to N-butyl-N-(3-carboxypropyl) nitrosamine, principal urinary metabolite of a potent bladder carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine. Chem Pharm Bull 1978; 26: 3909-13.
11. Fukushima S, Murasaki G, Hirose M, Nakanishi K, Hasegawa R, Ito N. Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in rats. Acta Pathol Jpn 1982; 32: 243-50.
12. Morstyn G, Hsu S-M, Kinsella T, Gratzner H, Russo A, Mitchell JB. Bromodeoxyurinide in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest 1983; 72: 1844-50.
13. Ozaki K, Sukata T, Yamamoto S et al. High sensitivity of p53 (+/-) knockout mice in N-butyl-N-(4-hydroxybutyl) nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 1998; 58: 3806-11.
14. Mori Y, Yanazaki H, Toyoshi K et al. Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction. Carcinogenesis 1985; 6: 415-20.
15. Nagao M, Suzuki E, Yasuo K, Yahagi T, Seino Y. Mutagenicity of N-butyl-N-(4-hydroxybutyl) nitrosamine, a bladder carcinogen, and related compounds. Cancer Res 1977; 37: 399-407.
16. Mori Y, Koide A, Fuwa K, Kobayashi Y. N-benzylimidazole for preparation of S9 fraction with multi-induction of metabolizing enzymes in short-term genotoxicity assays. Mutagenesis 2001; 16: 479-86.
17. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-8.
18. Mori Y, Niwa T, Toyoshi K. Participation of cytochrome P450 in mutagenic activation of the carcinogen 3′-hydroxymethyl-N, N-dimethyl-4-aminoazobenzene and its N-demethylated compounds by rat liver. Mutat Res 1983; 122: 13-22.
19. Koide A, Fuwa K, Furukawa F, Hirose M, Nishikawa A, Mori Y. Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver. Mutat Res 1999; 428: 165-76.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
21. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
22. Mori Y, Koide A, Fuwa K, Wanibuchi H, Fukushima S. Lack of change in the levels of liver and kidney cytochrome P-450 isozymes in p53+/- knockout mice treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Mutagenesis 2001; 16: 377-83.
23. Waldman FM, Carroll PR, Cohen MB, Kerschmann R, Chew K, Mayall BH. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder. Mod Pathol 1993; 6: 20-4.
24. Tatematsu M, Fukushima S, Aoki T, Mera Y, Inoue T, Ito N. Patterns of epithelial proliferation revealed by continuous administration of bromodeoxyuridine during urinary bladder carcinogenesis in rats. Jpn J Cancer Res 1987; 78: 879-82.
25. Einarsson K, Gustafsson J-A, Stenberg A. Neonatal imprinting of liver microsomal hydroxylation and reduction of steroids. J Biol Chem 1973; 248: 4987-97.
26. Levin W, Ryan D, Kuntzman R, Conney AH. Neonatal imprinting and the turnover of microsomal cytochrome P-450 in rat liver. Mol Pharmacol 1975; 11: 190-200.
27. Shimada M, Murayama N, Yamazoe Y, Kamataki T, Kato R. Further studies on the persistence of neonatal androgen imprinting on sex-specific cytochrome P-450, testosterone and drug oxidations. Jpn J Pharmacol 1987; 45: 467-78.
28. Kihara K, Fukui I, Higashi Y, Oshima H. Inhibitory effect of testosterone on gap junctional intercellular communication of human transitional cell carcinoma cell lines. Cancer Res 1990; 50: 2848-52.
29. Suzuki E, Anjo T, Aoki J, Okada M. Species variations in the metabolism of N-butyl-N-(4-hydroxybutyl) nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Jpn J Cancer Res [Gann] 1983; 74: 60-8.
30. 6-(4-hydroxybutyl) guanine in urothelial and hepatic DNA of rats given the bladder carcinogen N-nitrosobutyl (4-hydroxybutyl) amine. Carcinogenesis 1994; 15: 2297-301.
31. Airoldi L, Magagnotti C, De Gregorio G, Moret M, Fanelli R. In vitro metabolism of bladder carcinogenic nitrosamines by rat liver and urothelial cells. Chem Biol Interact 1992; 82: 231-40.
32. Bonfanti M, Magagnotti C, Bonati M, Fanelli R, Airoldi L. Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl) amine in rats. Cancer Res 1988; 48: 3666-9.
33. Mochizuki M, Irving CC, Anjo T, Wakabayashi Y, Suzuki E, Okada M. Synthesis and mutagenicity of 4-(N-butylnitrosamino)-4-hydroxybutyric acid lactone, a possible activated metabolite of the proximate bladder carcinogen N-butyl-N-(3-carboxypropyl) nitrosamine. Cancer Res 1980; 40: 162-5.
34. Druckrey H, Preussmann R, Ivankovic S et al. Organotrope carcinogene wirkungen bei 65 verschiedenen N-nitroso-verbindungen an BD-Ratten. Z Krebsforsch 1967; 69: 103-201.
35. Magee PN, Barnes JM. Carcinogenic nitroso compounds. Adv Cancer Res 1967; 10: 163-246.
36. Masuko T, Sugahara K, Nakajima S, Hashimoto Y. Altered expression of immunohistochemically detected cytochrome P-450 component(s) in nitrosamine-induced rat urinary bladder lesion. Jpn J Cancer Res 1987; 78: 840-5.
37. Irving CC, Daniel DS. Influence of disulfiram on the metabolism of the urinary bladder carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine in the rat. Carcinogenesis 1987; 8: 1309-15.
38. Pastorelli R, Ancidei A, Benfenati E, Fanelli R, Airoldi L. Effect of butylated hydroxyanisole added in vitro or administered to rats on N, N-dibutylnitrosamine and N-butyl-N-(4-hydroxybutyl) nitrosamine metabolism by post-mitochondrial supernatant of liver homogenates. Toxicology 1988; 48: 71-80.
39. Irving CC. Oxidation of N-butyl-N-(3-formylpropyl) nitrosamine to N-butyl-N-(3-carboxypropyl) nitrosamine in rat liver and inhibition by disulfiram. Carcinogenesis 1988; 9: 2109-12.
40. Irving CC, Daniel DS. Inhibition of the oxidation of the urinary bladder carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine by pyrazole and 4-substituted pyrazoles. Biochem Pharmacol 1988; 37: 1642-4.
41. Matsunaga T, Iwawaki Y, Watanabe K et al. Cytochrome P450 isozymes catalyzing the hepatic microsomal oxidation of 9-anthraldehyde to 9-anthracene carboxylic acid in adult male rats. Biol Pharm Bull 1993; 16: 866-9.
42. Matsunaga T, Shibayama K, Higuchi S, Tanaka H, Watanabe K, Yamamoto I. Characterization of microsomal alcohol oxygenase catalyzing the oxidation of 7-hydroxy-delta 8-tetrahydrocannabinol to 7-oxo-delta 8-tetrahydrocannabinol in rat liver. Biol Pharm Bull 2000; 23: 43-6.
43. Messiha FS. Effect of centrally acting drugs on ethanol detoxification enzymes in distinct rat brain regions. Neurobehav Toxicol Teratol 1985; 7: 181-4.
44. Kishimoto R, Ogishi Y, Ueda M et al. Gender-related differences in mouse hepatic ethanol metabolism. J Nutr Sci Vitaminol (Tokyo) 2002; 48: 216-24.
45. Simon FR, Fortune J, Iwahashi M, Sutherland E. Sexual dimorphic expression of ADH in rat liver: importance of the hypothalamic-pituitary-liver axis. Am J Physiol Gastrointest Liver Physiol 2002; 283: G646-55.
46. Imaoka S, Yoneda Y, Sugimoto T et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett 2001; 166: 119-23.
47. Schulze J, Richter E, Philpot RM. Tissue, species, and substrate concentration differences in the position-selective hydroxylation of N-nitrosodibutylamine. Relationship to the distribution of cytochrome P-450 isozymes 2 (IIB) and 5 (IVB). Drug Metab Dispos 1990; 18: 398-402.
48. Imaoka S, Yoneda Y, Matsuda T, Degawa M, Fukushima S, Funae Y. Mutagenic activation of urinary bladder carcinogenesis by CYP4B1 and the presence of CYP4B1 in bladder mucosa. Biochem Pharmacol 1997; 54: 677-83.